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REGULAR ARTICLE
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Induction of fetal hemoglobin (HbF) via clustered regularly interspaced short palindromic
repeats/Cas9–mediated disruption of DNA regulatory elements that repress g-globin gene
(HBG1 andHBG2) expression is a promising therapeutic strategy for sickle cell disease (SCD)
and b-thalassemia, although the optimal technical approaches and limiting toxicities are
not yet fully defined. We disrupted an HBG1/HBG2 gene promoter motif that is bound
by the transcriptional repressor BCL11A. Electroporation of Cas9 single guide RNA
ribonucleoprotein complex into normal and SCD donor CD341 hematopoietic stem and
progenitor cells resulted in high frequencies of on-target mutations and the induction of HbF
to potentially therapeutic levels in erythroid progeny generated in vitro and in vivo after
transplantation of hematopoietic stem and progenitor cells into nonobese diabetic/severe
combined immunodeficiency/Il2rg2/2/KitW41/W41 immunodeficient mice. On-target editing
did not impair CD341 cell regeneration or differentiation into erythroid, T, B, or myeloid cell
lineages at 16 to 17 weeks after xenotransplantation. No off-target mutations were detected
by targeted sequencing of candidate sites identified by circularization for in vitro reporting
of cleavage effects by sequencing (CIRCLE-seq), an in vitro genome-scale method for
detecting Cas9 activity. Engineered Cas9 containing 3 nuclear localization sequences edited
human hematopoietic stem and progenitor cells more efficiently and consistently than
conventional Cas9 with 2 nuclear localization sequences. Our studies provide novel and
essential preclinical evidence supporting the safety, feasibility, and efficacy of amechanism-
based approach to induce HbF for treating hemoglobinopathies.
Introduction
Sickle cell disease (SCD) and b-thalassemia are common disorders caused by HBB gene mutations
that alter quantity or quality of the b-globin subunit of adult hemoglobin (HbA, a2b2).1,2 Severely
affected individuals experience multiorgan damage, with substantial morbidity and early mortality.
Αllogeneic hematopoietic stem cell (HSCs) transplantation can be curative but carries high risk of
severe toxicities, particularly for patients who lack fully histocompatible donors.3 Hence, new methods
for autologous gene therapy are being sought.
Submitted 8 August 2019; accepted 19 August 2019. DOI 10.1182/
bloodadvances.2019000820.
*J.-Y.M., P.A.D., and T.M. contributed equally to this study.
The full-text version of this article contains a data supplement.
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Genome editing of patient HSCs by clustered regularly inter-
spaced short palindromic repeats (CRISPR)–Cas9 nucleases
represents a promising approach for genetic correction of
b-hemoglobinopathies.4-6 These nucleases introduce targeted
DNA double-stranded breaks (DSBs) that can be exploited
therapeutically through 2 general cellular DNA damage repair
strategies. First, HBB mutations can be corrected via homology-
directed repair (HDR).5,7-12 Second, fetal hemoglobin (HbF, a2g2)
can be induced in adult red blood cells (RBCs) by using
nonhomologous end-joining (NHEJ) mediated mutations to disrupt
noncoding DNA regulatory elements that repress transcription of
the genes encoding g-globin (HBG1 and HBG2) postnatally.4,13-19
Numerous clinical studies show that elevated HbF production
is associated with reduced morbidity and mortality in SCD and
b-thalassemia.20,21 In extreme cases, a rare, benign genetic
condition called hereditary persistence of HbF (HPFH) induces
high-level pancellular HbF expression in RBCs and eliminates the
pathologies of coinherited b-hemoglobinopathies.22 Therapeuti-
cally, the induction of HbF by NHEJ may offer several advantages
over direct HBB repair for treating b-hemoglobinopathies. First,
NHEJ is the dominant DNA DSB repair pathway and is active in all
phases of the cell cycle, which is particularly relevant to editing
quiescent HSCs. Second, correction of the SCD mutation via HDR
is accompanied by undesired NHEJ-mediated insertion/deletion
(indel) mutations in cis or trans.7,23 Third, in contrast to HDR, NHEJ
does not require delivery of an exogenous DNA donor template,
which introduces additional technical challenges in manufactur-
ing. Lastly, genome editing to induce HbF provides a single
generally applicable therapeutic strategy for many different
b-hemoglobinopathy mutations, whereas correction by HDR
would require mutation-specific optimization.
Several HPFH mutations occur in a region 118 to 114 nt upstream
of the HBG1 and HBG2 transcription start sites and disrupt
a cognate-binding element for the g-globin gene repressor
BCL11A (TGACC).24,25 Previously, we targeted this region in
CD341 hematopoietic stem and progenitor cells (HSPCs) by
lentiviral expression of Cas9 and associated single guide RNAs
(sgRNAs) followed by in vitro differentiation.16 The percentage of
HbF (%HbF) was increased to potentially therapeutic levels in the
RBC progeny of most CD341 cells with on-target edits. Here we
advance that proof-of-concept study by achieving several essential
requirements for clinical translation, including transient Cas9:
sgRNA delivery to HSPCs, high-level editing in human HSCs
capable of multilineage engraftment after transplantation into
immunodeficient mice, and absence of detectable off-target
mutations or deleterious hematopoietic effects. Therefore, Cas9
ribonucleoprotein (RNP)–mediated disruption of the BCL11A
repressor binding site in the promoters of HBG1 and HBG2 is




Plerixafor-mobilized CD341 cells from patients with SCD were
collected according to the protocol Peripheral Blood Stem Cell
Collection for Sickle Cell Disease Patients (www.clinicaltrials.gov
identifier #NCT03226691), which was approved by the human
subject research institutional review boards at the National
Institutes of Health and St. Jude Children’s Research Hospital. All
patients provided informed consent.
Animal care
Mice were housed and handled in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. Animal experiments
were carried out in accordance with a protocol (Genetic Tools for
the Study of Hematopoiesis) approved by the institutional animal
care and use committee of the St. Jude Children’s Research
Hospital or Boston Children’s Hospital.
Cell culture, editing, and xenotransplantation
The antibodies used in this study are listed in supplemental Table 1.
The cytokines used are listed in supplemental Table 2. The
oligonucleotides used are listed in supplemental Table 3. The
isolation, editing, and analysis of CD341 cells before and after
xenotransplantation are described in the supplemental Methods.
Results
Optimization of HBG1/HBG2 promoter editing in
human CD341 cells via Cas9:sgRNA RNPs
We edited human CD341 HSPCs by electroporating RNP
complexes of Cas9:sgRNA-1 targeting the BCL11A consensus
motif at position 2118 to 2114 in the HBG1/HBG2 gene
promoters (Figure 1A). Initial studies were performed using the
Neon Transfection System (see supplemental Methods). We
titrated Cas9 and sgRNA-1 with or without 29-O-methyl modifica-
tions and 39-phosphorothioate internucleotide linkages shown
previously to improve gene editing rates in primary cells26 and
electroporated the RNP complexes into adult human peripheral
blood–mobilized CD341 HSPCs. Transfected cells were cultured
for 4 days and then analyzed for small indels by next-generation
sequencing (NGS) of a 318-bp polymerase chain reaction (PCR)
fragment centered around the RNP cleavage site (Figure 1B;
supplemental Figure 1A-B). The maximum indel frequencies
observed were ;45% with unmodified sgRNA and 80% with
chemically modified sgRNA. After electroporation, cell viability
declined with increasing RNP concentration but remained .80%
under all conditions (supplemental Figure 1C-E). Importantly, the 9
most frequently observed indel alleles, and presumably most others,
disrupt the BCL11A-binding site and therefore are predicted to
derepress the associated g-globin genes (Figure 1C).
Gene editing induces HbF expression in cultured
erythroid cells
We cultured gene-edited CD341 HSPCs from 2 donors under
erythroid differentiation conditions and measured the HbF expres-
sion in late-stage erythroblasts. The mean indel frequency
measured was 63% 6 18% (Figure 2A). As usual for in vitro–
derived erythroblasts, background HbF expression was high;
;50% of the cells stained with HbF antibody (termed F-cells),
and HbF protein constituted ~10% of the total Hb in cell lysates
(Figure 2B-C; supplemental Figure 2). Nonetheless, gene editing of
the HBG1 and HBG2 gene promoters raised %F-cells and %HbF
protein significantly. Editing did not alter the expression of erythroid
maturation markers Band3 or CD49d (Figure 2D) or the conversion
of nucleated erythroblasts to anucleate reticulocytes (Figure 2E).
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Gene editing of HSCs induces HbF expression in
erythroid progeny generated in vivo
To assess our capacity to edit repopulating HSCs, we electro-
porated CD341 cells with Cas9:sgRNA-1 RNP and transplanted
them into nonobese diabetic/severe combined immunodeficiency/
Il2rg2/2/KitW41/W41 (NBSGW) mice, an immunodeficient strain
that supports the development of human erythroid precursors
without conditioning.27 We measured the fraction of engrafted
human cells and their indel frequencies serially in blood and in bone
marrow after the mice were euthanized at 17 weeks, when donor
CD341 cells present derive mainly from HSCs.27 No significant
differences in chimerism occurred between edited and nonedited
donor-derived CD451 hematopoietic cell populations (Figure 3A).
Chimerism levels were similar for edited and nonedited donor
T cells (hCD451/CD31), B cells (hCD451/CD191), myeloid cells
(hCD451/CD331), and erythroid cells (CD452/CD235a1) in bone
marrow at 17 weeks (Figure 3B).
The indel frequencies of edited human donor cells declined from
70.9% 6 5.8% a few days after editing to 41.8% 6 9.4% at
17 weeks after xenotransplantation (Figure 3C), similar to what has
been reported previously.14,23,28 Notably, the 13-nt HPFH mutation
occurred at similar frequencies in CD341 HSPCs before and after
transplantation (Figure 3C; supplemental Figure 3). Indel frequen-
cies were also similar in CD341 donor cell–derived myeloid,
erythroid, and B cells (Figure 3D), indicating that editing did not alter
the development of these lineages from HSCs. The indel spectrum
in edited cells was similar before and after transplantation, with no
clonal dominance in the latter populations (Figure 3E; supplemental
Figure 3).
Circulating human RBCs are short lived and difficult to detect
in mouse xenotransplantation studies. Therefore, we studied
immune-selected CD235a1 donor-derived erythroblasts from the
bone marrow of recipient mice at 17 weeks after transplantation.
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Figure 1. Cas9:sgRNA RNP disruption of a transcriptional repressor binding motif in the g-globin gene promoters. (A) The extended b-globin locus, showing the
target BCL11A binding motif in the promoters of the genes encoding g-globin (HBG2 and HBG1). The 13-nt HPFH deletion is indicated by a dashed black line. sgRNA-1
target is represented by a black line, with a vertical arrow indicating the predicted site of Cas9 dsDNA cleavage and the protospacer adjacent motif (PAM) sequence indicated
in gray. (B) Optimization of the Cas9:sgRNA-1 ratio on indel formation, using the Neon Transfection System. RNPs were generated by incubating the indicated amounts of
Cas9 and sgRNA in 5 mL of 10 mM HEPES, 150 mM NaCl for 30 min at room temperature. Here and in subsequent experiments, sgRNA-1 was chemically modified to
enhance stability. The RNPs were mixed with 2 3 105 CD341 cells in T buffer in a final volume of 10 mL, electroporated using a Neon Transfection System at 1600 V, with
3 pulses of 10 ms, cultured for 4 days, and then analyzed for indel formation by high-throughput sequencing of PCR products generated using primers located ;150 bp on
either side of the RNP cleavage site. The graphs show the mean 6 standard deviation (SD) indel frequency on the y-axis (n 5 3 biological replicates). Dark blue indicates the
13-nt human HPFH mutation; light blue represents all other indels. (C) Sequence alignment of the most common mutant alleles. The sgRNA-1 sequence is underlined and
bolded, the PAM sequence is in red, and the BCL11A-binding motif is highlighted in blue. Deletions are represented by dashes. The percentage of each mutation observed is
shown on the right, with the NGS read counts in parentheses. LCR, locus control region.
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reticulocytes, with no obvious differences in morphology, expres-
sion of maturation markers, or enucleation fraction between the
edited and control populations (Figure 3F-H). Notably, background
%HbF was lower in control (nonedited) erythroblasts generated
in vivo compared with in vitro cultures (compare Figure 2B-C to
Figure 3I-J). The percentages of both HbF-immunostaining cells
(F cells) and HbF protein compared with overall Hb were significantly
increased in edited vs control erythroid cells generated in vivo (Figure
3I-J). Considering that the F-cell fraction was 51.3% 6 12.5% in
erythroblasts with;42% indels (Figure 3D), it is likely that HbF was
induced in all edited cells, thereby favoring therapeutic efficacy.29
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Figure 2. Gene editing induces HbF expression in cultured erythroid cells. G-CSF–mobilized CD341 cells were edited with Cas9:sgRNA-1 RNP using the Neon
Transfection System (supplemental Methods). They were then grown in culture for 21 days under conditions that support erythroid differentiation. Data show studies from 2
different CD341 cell donors (blue or red), with each dot representing separate experiments. (A) Indel frequencies in gene-edited (RNP) and control (C) groups determined
4 days after editing. Dark blue indicates the 13-nt human HPFH mutation; light blue represents all other indels. (B) Cells immunostaining for hemoglobin F (F-cells) measured
by flow cytometry at culture day 21. (C) The %HbF in day 21 erythroid cell lysates determined by ion-exchange high-performance liquid chromatography (HPLC). The bar
charts in panels A-C show the results as the mean 6 SD. **** P , .0001 (unpaired Student t test). (D) Erythroid maturation kinetics at culture days 7, 14, and 21, as
determined by immunoflow cytometry measurement of CD49d and Band3 expression on CD235a1 erythroid cells. (E) Enucleated cell fractions at culture days 14, 17, and 21,
as determined by flow cytometry for CD235a and the cell-permeable DNA dye Hoechst 333412. The numbers in each quadrant show the mean percentages 6 SDs. The data
reflect studies of CD341 cells from 2 different donors in 7 independent experiments.
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Figure 3. Xenotransplantation of normal gene-edited CD341 cells into NBSGW mice. Peripheral blood (PB) CD341 cells were edited with Cas9:sgRNA-1 RNP using
the Neon Transfection System and then transplanted into NBSGW mice via tail-vein injection. Donor cell controls (C) were processed in parallel, but not electroporated.
Donor-cell progeny were analyzed in recipient peripheral blood at 6, 11, and 16 weeks and in bone marrow (BM) at 17 weeks after transplantation. Data are from 3 in-
dependent experiments with CD341 cells from different donors (red, blue, or green). Each dot in graphs represents a separate mouse. (A) Normalized human chimerism in
peripheral blood and bone marrow, shown as the percentage of human (h) CD451 cells. (B) Human T (CD31), B (CD191), and myeloid (M) (CD331) cells shown as
percentages of the human CD451 population in bone marrow at 16 weeks. Erythroid chimerism (E) is shown as the percentage of human CD235a1 cells within the CD452
population (mouse and human). (C) The indel fraction 4 days after editing (Pre BMT) and as measured serially after xenotransplantation. Dark blue represents the 13-nt human
HPFH mutation; light blue represents all other indels. (D) Indels in specific hematopoietic lineages. Dark blue represents the 13-nt human HPFH mutation; light blue represents
all other indels. (E) The most frequent indels in donor 1 CD341 cells before bone marrow transplantation and in the 16-week bone marrow of mouse recipients. Unique indels
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(Figure 3K). These xenotransplantation studies demonstrate that it
is feasible to induce erythroid HbF expression by Cas9 RNP-
mediated disruption of the HBG1/HBG2 BCL11A-binding motif,
with no obvious alterations in hematopoietic development in vivo.
A 4.9-kb deletion arising from simultaneous
double-stranded DNA (dsDNA) cleavage at HBG1 and
HBG2 on-target sites
The tandem HBG1 and HBG2 genes harbor nearly identical
nucleotide sequences, including recognition sites for sgRNA-1.
Simultaneous RNP-induced DSBs at both genes can result in the
deletion of the intervening 4.9-kb region,16,30 leaving a single hybrid
gene with HBG2 promoter sequences fused to the downstream
HBG1 gene (Figure 4A). We developed 2 assays as proxies for the
4.9-kb deletion. First, we used a TaqMan quantitative PCR assay to
quantify loss of DNA in the HBG2-HBG1 intergenic region
$366 bp upstream of the RNP cleavage site (“D3661”). Second,
we PCR-amplified exon 3 of HBG1 and HBG2, using a common
primer pair, and performed NGS to quantify loss of HBG2
(“DHBG2”) based on a single-nucleotide difference between
HBG2 and HBG1 (G vs C at cDNA position 410) (Figure 4A).
Both assays showed that the 4.9-kb deletion rates were ;30%
before transplantation and 11% at 17 weeks posttransplantation
(Figure 4B). By comparison, small indel rates were;72% and 43%
before and after transplantation, respectively.
To measure large indels clonally and investigate whether the
associated loss of HBG2 impaired HbF production, we analyzed
burst-forming unit erythroid (BFU-E) colonies from edited and
control CD341 cells (Figure 4C). The frequency of hematopoietic
colonies was decreased by ;30% in CD341 cells electroporated
with Cas9:sgRNA-1 RNP vs Cas9 alone (supplemental Figure 4A),
with the proportions of myeloid and erythroid colonies being similar
(supplemental Figure 4B). In pools of;1000 gene-edited colonies,
the small indel frequency was 57.3% (supplemental Figure 4C) and
the %HbF increased from 8.1% 6 0.6% in controls to 27.7% 6
2.5% after editing (supplemental Figure 4D). In 124 BFU-E colonies
analyzed individually, the frequency of small on-target indels was
45%, and the frequency of large indels measured by loss of HBG2
exon 3 was 24% (Figure 4C). Colonies with no on-target edits
contained 9.5% 6 5.8% HbF (n 5 47). Most edited colonies
contained either 4 g-globin alleles, all with small indels that
disrupted BCL11A binding motifs (n 5 15; HbF, 48.4% 6 30%),
or 1 deleted HBG2 allele with the BCL11A-binding motifs
disrupted in the 3 remaining g-globin genes (n 5 28; HbF, 40.8%
6 17%). Thus, the loss of a single HBG2 allele, presumably
reflecting the 4.9-kb deletion, did not appreciably alter the %HbF.
Simultaneous dsDNA breaks at the HBG1 and HBG2 promoters
can also cause inversion of the intervening DNA (Figure 4D),
predicted to eliminate the expression of both genes. Using primer
pairs that detect this inversion, we identified multiple PCR products
specifically in edited HUDEP-2 cells and CD341 HSPCs. Sanger
sequencing showed that these inverted segments contained
interrupted sequences and deletions ranging from 236 to 1916
bp. We detected the inversion in 1 of 96 BFU-E colonies (1%)
generated from bulk-edited CD341 HSPCs with an overall on-
target small indel frequency of 84%. Thus, this inversion likely
occurs at low rates.
Cas9:sgRNA-1 RNP cleaves DNA specifically
We characterized the genome-wide activity of Cas9:sgRNA-1 by
incubating RNP with purified genomic DNA followed by circulari-
zation for in vitro reporting of cleavage effects by sequencing
(CIRCLE-seq), a sensitive in vitro method for enriching for Cas9-
cleaved genomic DNA and identifying the breakpoints by NGS.31 In
3 experimental replicates, we consistently detected 26 potential off-
target candidate sites (Figure 5, left panel). However, no mutations
were detected at these sites by NGS of PCR products generated
from edited HSPCs (sensitivity 0.1%-0.01%) (Figure 5, right panel).
At $16 weeks after xenotransplantation, gene-edited human donor
cells contained no chromosomal rearrangements detected by
G-band karyotyping (supplemental Figure 5) or fluorescence
in situ hybridization (FISH) with a probe located distal to the
g-globin gene loci on human chromosome 11 (supplemental
Figure 6). Overall, our data suggest that Cas9:sgRNA-1 RNP
targets the HBG1 and HBG2 promoters with high specificity and
without detectable off-target DNA mutations at the sites analyzed.
Genome editing of HSCs from patients with SCD
induces HbF expression in erythroid progeny
We next analyzed the effects of Cas9:sgRNA-1 gene editing in
CD341 HSPCs from 2 individuals with SCD. As granulocyte
colony-stimulating factor (G-CSF) is contraindicated in SCD,32,33
we edited plerixafor-mobilized peripheral blood CD341 cells. After
xenotransplantation into NBSGW mice, edited and control (non-
edited) CD341 cells populated the bone marrow similarly
(Figure 6A) and gave rise to similar fractions of human T, B,
myeloid, and erythroid cells (Figure 6B). For SCD donor 1, the small
on-target indel frequency was 79% before transplantation and
remained high at 16 weeks after transplantation (72% 6 3%)
(Figure 6C). For SCD donor 2, the indel frequency was 55% before
transplantation and declined to 18% 6 2% after transplantation.
The spectrum of on-target indels in SCD CD341 HSPCs was
similar to that observed after editing normal G-CSF–mobilized
Figure 3. (continued) are shown with a different color, with the bar size representing the relative abundance. The 13-nt HPFH mutation is represented in black. All indels
present in proportions ,1% are represented collectively in blue at the top of each bar. (F) Morphology of human CD235a1 erythroblasts in bone marrow of recipient mice
transplanted with RNP-edited or control CD341 cells. The images were acquired with a Nikon Eclipse Ni microscope with a 603 objective and Nikon NIS-Elements software
(scale bars, 10 mm). (G) Flow cytometry for the erythroid maturation markers CD49d and Band3 on human CD235a1 erythroblasts in recipient mouse bone marrow. (H)
Enucleated (HOECHST2) and nucleated (HOECHST1) human CD235a1 erythroblasts in recipient bone marrow. The numbers in panels G-H represent the mean 6 SD of the
percentage for the same samples analyzed in panels A-D. (I) The fraction of CD235a1 F-cells in bone marrow. (J) The %HbF in human CD235a1 erythroblasts isolated from
recipient bone marrow. (K) The %HbF as a function of the indel percentage from the values plotted in panels C and J. The bar charts in panels A-D and I-J show the mean 6
SD percentages for 3 biological replicates performed using CD341 cells from 3 donors. Each dot represents a single recipient mouse, and each color represents a separate
replicate study. ****P , .0001 (by unpaired Student t test).
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Figure 4. Consequences of on-target editing of HBG1 and HBG2. (A) Scale diagram of the HBG1 and HBG2 genes with exons shown as rectangles and on-target
Cas9:sgRNA-1 DNA cleavage sites indicated by vertical black arrows. The genes differ by a single nucleotide in exon 3 (open arrows). Primer pair If1Ir amplifies a region
surrounding the RNP cleavage site of both genes; NGS of this PCR product identified small on-target indels. Larger deletions presumed to arise from simultaneous dsDNA
breaks in HBG2 and HBG1, with the loss of the intervening 4.9 kb (dotted line), were indicated by 2 proxy methods. “DHBG2” denotes dropout of HBG2 exon 3 based on
the single-nucleotide difference between HBG2 and HBG1, determined by high-throughput sequencing of PCR products generated by a single primer pair (not shown).
“D3661” denotes a quantitative TaqMan PCR assay that detects deletions $366 nt upstream of the Cas9:sgRNA-1 cleavage site in HBG1. (B) Large deletions detected by
the DHBG2 and D3661 assays in CD341 cells 4 days after editing (Pre-BMT) and 17 weeks after xenotransplantation (Post-BMT). Data reflect studies from 2 different
CD341 cell donors (blue or red dots), with each dot after bone marrow transplantation representing a single mouse. (C) Mutational analysis and %HbF in single BFU-E
colonies. Each dot represents a BFU-E colony grouped by number of 4.9-kb deletions (Del) using the DHBG2 assay as proxy and the number of indels in the remaining
BCL11A binding motifs of HBG2, HBG1, or the modified HBG1 fusion gene formed by deletion repair. Thus, heterozygosity for the 4.9-kb deletion leaves 3 potential remain-
ing BCL11A-binding motifs and associated HBG coding regions, whereas homozygosity leaves only 2 such motifs. The bars represent the percentages of HbF as the
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CD341 HSPCs and did not change appreciably after xenotrans-
plantation (supplemental Figure 7).
The frequency of 4.9-kb HBG2-HBG1 intergenic deletions in
edited SCD donor 1 CD341 cells detected by the DHBG2 and
D3661 assays (Figure 4A) was ;30% before transplantation and
33% after transplantation (Figure 6D). These large deletions were
less frequent in edited SCD donor 2 CD341 cells, consistent with
relatively low frequencies of small indels. At 16 weeks after
xenotransplantation with edited SCD donor 1 HSPCs, we purified
donor CD341 cells and analyzed them by FISH using a probe for
the HBG2-HBG1 intergenic region and a control probe for an
adjacent downstream region including the HBB gene (supplemen-
tal Figure 8A). Most cells derived from gene-edited donor HSPCs
(42 of 75 cells analyzed) were heterozygous for the 4.9-kb HBG2-
HBG1 intergenic deletion (overall allele frequency, 32%) (supple-
mental Figure 8B).
At 16 weeks after transplantation, bone marrow erythroblasts
derived from gene-edited and control CD341 HSPCs exhibited
similar morphologies (Figure 6E) and maturation profiles as
determined by flow cytometry (supplemental Figure 9A-B). Eryth-
roblasts derived from gene-edited HSPCs from SCD patient 1
CD341 cells contained 77.8% 6 1.9% F cells as compared with
Figure 4. (continued) means 6 SDs. **P , .01, ***P , .001, ****P , .0001 (by unpaired Student t test). (D) Inversions resulting from simultaneous editing of HBG2 and
HBG1 target sites were characterized by PCR analysis using the indicated primer pairs. The agarose gel image shows PCR products from the bulk-edited HUDEP-2 (H2)














































































Figure 5. No off-target mutations are detected by a sensitive assay in CD34
1
HSPCs after editing at the g-globin gene promoters. Purified genomic DNA from
normal CD341 cell–derived erythroblasts was analyzed by the CIRCLE-seq method for defining Cas9 genome-wide activity in vitro. The left panel shows the 25 most frequent
candidate off-target sites for Cas9:sgRNA-1 RNP identified by CIRCLE-seq analysis on purified genomic DNA. The on-target sites including sgRNA and PAM sequences are
shown at the top. Off-target sites are ordered by CIRCLE-seq read count, with matches to the intended target site shown as dots and mismatches shown as colored nucleo-
tides. The right panel shows the indel frequencies at candidate off-target sites validated by targeted high-throughput sequencing of CD341 HSPCs edited with Cas9:sgRNA-1
RNP using the Neon Transfection System (blue squares) and control nonedited CD341 cells (red circles). The threshold of detection for NGS is ;0.01% to 0.1%.


























































C RNP C RNP














C RNP C RNP
























































Control (SCD #1) RNP (SCD #1)
E



























SCD #1 SCD #2
Figure 6. HBG1 and HBG2 promoters in CD341 HSPCs from individuals with SCD induces HbF expression in erythroid progeny generated after
xenotransplantation. Plerixafor-mobilized CD341 cells from 2 individuals with SCD (represented by blue and red) were edited with Cas9:sgRNA-1 RNP by using the Neon
Transfection System. They were then transplanted into NBSGW mice via tail-vein injection. Donor-cell controls (C) were processed in parallel, but not electroporated. Donor
cells were analyzed in recipient bone marrow at 16 to 18 weeks after transplantation. (A) Normalized human cell chimerism (hCD45%) in bone marrow for the 2 SCD donors.
(B) Chimerism for specific human lineages in recipient bone marrow, labeled as in Figure 3B. (C) The indel fraction in CD341 cells at 4 days after gene editing (Pre) and in
bone marrow after xenotransplantation. Dark blue represents the fraction of indels with the 13-nt HPFH deletion; light blue represents all other indels. (D) Large deletions were
quantified by the DHBG2 and D3661 assays (Figure 4A) in edited CD341 cells before 16 weeks after transplantation. (E) Morphology of human CD235a1 erythroblasts in
bone marrow of mice transplanted with control or RNP-edited CD341 cells. The images were acquired using a Nikon Eclipse Ni microscope with a 603 objective and Nikon
NIS-Elements software (scale bars, 10 mm). (F) The F-cell fraction in bone marrow CD235a1 erythroblasts. (G) The %HbF in CD235a1 erythroblasts isolated from recipient
bone marrow, as determined by ion-exchange HPLC. (H) The correlation of the %indels with the %HbF in CD235a1 erythroblasts isolated from recipient bone marrow.
(I) Human erythroblasts isolated from mouse recipient bone marrow were incubated for 8 hours in 2% O2 and visualized by phase-contrast microscopy using the IncuCyte
S3 Live-Cell Analysis System (Sartorius) with a 203 objective. The white arrowheads indicate cells with sickle-like morphology. (J) The sickled cell fraction after hypoxia in
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15.7% 6 1.6% in control nonedited erythroblasts (Figure 6F;
supplemental Figure 9C). The %HbF was 42.9% 6 1.5% after
gene editing vs 1.3% 6 0.5% in control erythroblasts (Figure 6G).
Erythroblasts generated in vivo from HSPCs from SCD patient 2
also exhibited substantially increased HbF induction after un-
dergoing gene editing, despite lower on-target indel frequencies
(Figure 6C,F-G). HbF induction in SCD erythroid cells correlated
with indel formation (Figure 6H), similar to that which we observed
in erythroid cells derived from normal donor HSPCs (Figure 3K). To
investigate the potential therapeutic benefits of HbF induction, we
used immunomagnetic beads to purify CD235a1 erythroid cells
from the bone marrow of mice that had been transplanted with
HSPCs from SCD patient 1. After being subjected to hypoxia (2%
O2) for 8 hours, 32% 6 1.0% of control erythroid cells exhibited
sickled morphology as compared with 13.5% 6 1.0% of gene-
edited cells (Figure 6I-J). Thus, HbF induction resulting from Cas9:
sgRNA-induced disruption of the BCL11A-binding site of the
HBG1 and HBG2 gene promoters inhibits erythroid cell sickling.
Superior HSC gene editing by Cas9-3xNLS
Our findings demonstrate that genome editing of the HBG1 and
HBG2 promoters in HSCs induces HbF in erythroid progeny.
However, on-target indel frequencies varied between CD341 cell
donors and tended to decline over time after xenotransplantation
(Figures 3C and 6C). The Streptococcus pyogenes Cas9 protein
used in our studies described thus far contains 2 tandem C-terminal
SV40 nuclear-localization signals (NLSs; Cas9-2xNLS).34 We
recently reported improved gene editing of human HSPCs using
a modified SpCas9 containing a c-Myc–like NLS at the N terminus
and both SV40 and nucleoplasmin NLSs at the C terminus (Cas9-
3xNLS) (Figure 7A).35
To test whether Cas9-3xNLS edits HSPCs more consistently, we
electroporated RNP complexes containing sgRNA-1 and either Cas9-
2xNLS or Cas9-3xNLS into normal humanCD341 cells with the Lonza
Nucleofector 4-D platform and then measured the resulting indel
frequencies after 3 days of culture in HSC media. Cas9-3xNLS
maintained consistently high indel rates (65.9% to 84.2%) across 2
donors and 4 different delivery conditions, whereas under identical
conditions, Cas9-2xNLS/sgRNA-1 RNP generated more variable indel
rates, ranging from 24.1% to 82.1% (Figure 7B).
Next, we transfected Cas9-3xNLS/sgRNA-1 RNP into CD341
HSPCs from 2 normal donors and transplanted the cells into
NBSGW mice. At 16 weeks after transplantation, human hemato-
poietic chimerism in the bone marrow measured by human CD45
expression was 93.6% 6 0.9% for donor 1 and 56.5% 6 5.8% for
donor 2 (Figure 7C). This difference may arise from variation in the
fraction of repopulating HSCs within the bulk donor CD341 cell
population from different donors. Bone marrow chimerism for T, B,
myeloid, and erythroid cell populations was similar for edited and
control donor cells, although erythroid chimerism was low for donor
2 (Figure 7D). The indel frequencies measured by TIDE (tracking of
indels by decomposition36) of donor CD341 HSPCs were similar
before and after transplantation, ranging from 86% to 98%. The
frequency of the 4.9-kb intergenicHBG2-HBG1 deletion in CD341
donor cells at 16 weeks after transplantation estimated by the
TaqMan D3661 assay was;40% for donor 1 and 22% for donor 2
(Figure 7E). We purified donor-derived CD341 cells from recipient
bone marrow and cultured them under erythroid differentiation
conditions. The HbF level was 25%6 5% in RBCs derived from gene-
edited donor CD341 cells but only 6% 6 1% in control RBCs
(Figure 7F). Together, the results of these studies indicate that CD341
HSPCs edited with Cas9-3xNLS/sgRNA-1 RNP maintained consis-
tently high levels of editing after xenotransplantation. Although
additional comparisons are required, our experiments suggest that
optimized delivery of RNP with Cas9-3xNLS or similar enhanced-
activity variants should facilitate robust editing of theHBG1 andHBG2
promoters in long-term engrafting HSCs, with HbF being induced in
the RBC progeny to therapeutic levels for SCD and b-thalassemia.
Discussion
Previously, we demonstrated that Cas9-mediated disruption of
a repressor element in the HBG1 and HBG2 promoters induces
erythroid HbF expression.16 Here, we advance those results by
showing that transient expression of Cas9 RNPs in human CD341
cells results in high-frequency editing of the target site (#80%) in
repopulating HSCs with induction of HbF to potentially therapeutic
levels in RBC progeny and no detectable genotoxicity. Editing at
this site precisely disrupts a binding motif for the BCL11A
transcriptional repressor protein, consistent with findings that most
on-target indels activate HBG1/HBG2 transcription.16 Our study
generated several important new findings.
First, our methods achieved substantially higher rates of target-site
editing in HSCs than reported previously after transient expression
of Cas9 RNPs30 or transcription activator-like effector nucleases,37
which will likely translate to greater therapeutic benefits. The
variability of HSC editing that we observed in our studies using
Cas9-2xNLS could be due to differences in donors, CD341
mobilization methods (ie, G-CSF vs plerixafor), or CD341 cell
purification. Notably, the use of chemically modified sgRNA and
Cas9-3xNLS35 achieved consistently high editing activity across
donors and delivery methods, in contrast to a commonly used Cas9
with 2 SV40 NLSs fused to the C terminus (Cas9-2xNLS). The
improvement in editing by Cas9-3xNLS may arise from NLS signals
at both ends of the protein and/or the use of 3 unique NLS signals
that interact synergistically with nuclear import machinery.38
Second, our study demonstrates high-frequency editing (#70%) of
plerixafor-mobilized CD341 HSPCs from individuals with SCD,
which represents the cell product most likely to be manipulated
therapeutically. Increased HbF levels enhance the survival of
erythroblasts and mature RBCs in patients with b-thalassemia or
SCD.39-46 The therapeutic benefits of our strategy depend on the
fraction of repopulating HSCs edited and the resultant levels and
cellular distribution of HbF. Because circulating human RBCs are
cleared very rapidly in mice, we are unable to measure the survival
advantage conferred by gene editing. After allogeneic bone marrow
transplantation for SCD,;20% donor HSC chimerism can result in
100% circulating donor RBCs and marked clinical improvement.47,48
In natural history studies, pancellular HbF levels .20% to 30% are
Figure 6. (continued) edited and control cells was determined by analyzing micrographs such as those in panel I. More than 300 cells in 2 independent experiments were
scored by 2 blinded observers. All bar charts show data as the mean 6 SD. Each dot represents a single recipient mouse from donor 1 (blue) or 2 (red). ****P , .0001,
***P , .001, **P , .01, and *P , .05 (by unpaired Student t test).
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Figure 7. Improved genome editing of the HBG1 and HBG2 promoters in HSCs by Cas9-3xNLS. (A) Schematic overview of Cas9-2xNLS and Cas9-3xNLS proteins
showing locations of nuclear localization signals. (B) Normal human CD341 cells from 2 different donors (#1 and #2 represented by blue and red dots, respectively) were
edited using 4 different delivery methods with the Lonza 4D-Nucleofector platform (x-axis) with RNPs composed of sgRNA-1 and either Cas9-3xNLS (red bar) or Cas9-2xNLS
(blue bar), then cultured in CD341 cell maintenance medium (supplemental Table 2). Nonedited donor-cell controls (C) were processed in parallel, but not electroporated.
Indels were analyzed at day 3 by NGS. (C-F) Normal CD341 cells from 2 different donors were edited with the Lonza 4D-Nucleofector (EO-100 program) and RNP composed
of sgRNA-1:Cas9-3xNL and then transplanted into NBSGW mice. (C) Normalized chimerism of human CD451 donor cells in recipient bone marrow at 16 weeks after
xenotransplantation. (D) Chimerism for different human lineages, labeled as in Figure 3B. (E) Frequencies of small indels detected by TIDE assay and large (4.9 kb) deletions
detected by the D3661 assay (Figure 4A) in donor CD341 cells 5 days after editing (Pre) and 16 weeks after bone marrow transplantation. The 13-nt HPFH mutation is
indicated in dark blue; all other mutations are represented by light blue. (F) Donor CD341 cells were purified from recipient bone marrow and grown in culture for 18 days
under erythroid differentiation conditions. The bar chart shows %HbF as determined by ion-exchange HPLC. Each dot represents a biological replicate experiment with 2
different CD341 cell donors (blue and red). **P , .01 and ****P , .0001 (unpaired Student t test).
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suggested to protect against SCD morbidities, consistent with
biochemical studies of HbS polymerization.49-51 Based on these
parameters extrapolated from clinical studies, the preclinical outcomes
achieved in this study (70% to 80% indel rate in HSCs, with most or all
RBC progeny expressing HbF at an average level of 30% to 40%) are
likely to produce clinical benefits. One limitation of our study is that on-
target editing frequencies in HSCs varied considerably between
experiments and donors in initial experiments. However, our data using
newly developed Cas9-3xNLS suggest that consistent high-level
editing of theHBG1/HBG2 promoters in repopulating HSCs can now
be achieved, similar to what was recently reported for an erythroid-
specific enhancer in the BCL11A gene.35
Third, our study provides critical new preclinical safety assessments
by showing that the 4.9-kb deletion resulting from simultaneous
on-target DSBs in HBG1 and HBG2 promoters is not deleterious
to HSCs or RBC precursors. Analysis of clonal BFU-E colonies
showed that HbF expression was not impaired by deletion of
HBG2. In most clones harboring the 4.9-kb deletion, the BCL11A-
binding motif was destroyed at the DSB repair site, thereby favoring
expression of the reconstituted HBG1 gene. Expression of b-like
globin genes is facilitated via interaction with an upstream enhancer,
termed locus control region.52 Loss of HBG2 may eliminate
competition for the locus control region, thereby favoring upregulation
of the remainingHBG1 gene. Interestingly, a germline variant similar to
the 4.9-kb deletion noted in our study has been identified in multiple
unrelated individuals. This variant arises from unequal crossing over
between microsatellite markers in the second introns of HBG2 and
HBG1, resulting in a 5-kb deletion that generates a single chimeric
g-globin gene with exons 1 and 2 originating from HBG2 and exon 3
from HBG1.53,54 Individuals with this variant have RBCs with reduced
Gg to Ag ratio as infants but are otherwise normal throughout life.
These clinical observations, along with our experimental data, suggest
that the 4.9-kb deletion arising from our gene-editing strategy will not
have deleterious effects on globin expression, erythroid development,
or RBC physiology.
Additionally, our studies did not detect off-target DSBs in edited
HSCs at top candidate sites identified by CIRCLE-seq, and no
chromosomal abnormalities were detected by G-banding or FISH
analysis of .200 CD341 HSPCs after xenotransplantation. For
ultimate therapeutic application, it will be important to examine all
sites reproducibly identified by CIRCLE-seq after editing the HBG
promoters with Cas9-3xNLS and perform further assessments for
structural variants induced by our gene-editing protocol.
In summary, our studies demonstrate that it is possible to achieve
high-level editing of the HBG1/HBG2 promoters in G-CSF–mobilized
CD341 cells from normal individuals and plerixafor-mobilized CD341
cells from individuals with SCD, that editing does not impair
hematopoiesis, and that productive editing results in HbF induction
to potentially therapeutic levels, with no off-target DSBs or chromo-
somal rearrangements being detected. These preclinical safety and
efficacy studies support a promising strategy for modifying human
HSPCs to treat human b-hemoglobinopathies.
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